DarioHealth price target lowered to $10 from $16 at Stifel

Stifel lowered the firm’s price target on DarioHealth (DRIO) to $10 from $16 and keeps a Buy rating on the shares. The firm continues to model 2025 and 2026 revenue and EBITDA estimates below consensus as visibility on timing of the signing and ramp of contracts remains limited, adding that the stock is “unlikely to regain momentum until there is better visibility on revenue growth acceleration and achieving profitability.”